CALT - Calliditas files to sell up to $75M American depositary shares

Calliditas Therapeutics (NASDAQ:CALT) filed with the SEC for an at-the market-program to sell up to $75M American depositary shares (ADSs) at market price from time to time. The number of ADSs to be sold under the open market sale agreement with Jefferies will depend upon the number of underlying common shares approved for transfer under shareholder authorization received in May. The company expects to use the net proceeds to develop candidates from its NOX inhibitor platform, including setanaxib; fund commercial activities for TARPEYO, for developing Budenofalk in AIH; for potential acquisition/licensing of product candidates; and for working capital and other general corporate purposes. No transactions under the ATM program will take place on Nasdaq Stockholm.

For further details see:

Calliditas files to sell up to $75M American depositary shares